Zhi Tong Cai Jing·2025-08-18 07:05Core Viewpoint - CICC maintains the net loss forecast for Rongchang Biologics (09995) at RMB 915 million for 2025 and RMB 333 million for 2026, while raising the target price by 24.8% to HKD 95.34 due to positive clinical results of Taitasip and the approval of RC148 for Phase II trials in the U.S. [1] Group 1 - The positive results from the Phase III clinical trial of Taitasip for dry eye syndrome are expected to enhance its future value [1] - The approval of RC148 for Phase II clinical trials in the U.S. marks its entry into global clinical development, indicating its international clinical value and potential for overseas expansion [1] - The company plans to submit a marketing application for Taitasip to the National Medical Products Administration (NMPA) and will present detailed data at major international academic conferences [1]